Dr. Stadtmauer is Chief of the Hematologic Malignancies Section within the Division of Hematology-Oncology, Department of Medicine of the Perelman School of Medicine, at the University of Pennsylvania in Philadelphia, PA. He is also the Co-Leader of the Abramson Cancer Center Hematologic Malignancies Research Program and the Penn Medicine Hematologic Malignancies Translational Center of Excellence. He has been associated with the University for over 30 years. He was the Co-Chairman of the Bone Marrow Transplant Committee of the NCI-funded Eastern Cooperative Oncology Group (ECOG) for ten years and is a member of the Myeloma and Leukemia Core Committees. He has been associated with the Center for International Bone Marrow Transplant Research (CIBMTR) for over a decade with leadership positions including chair of the nominating committee, co-chair Solid Tumor Working Committee and member of the Clinical Trials Advisory Committee. He is also a founding member of the Steering Committee of the NIH-sponsored Blood and Marrow Transplant Clinical Trial Network (BMT CTN) and elected to serve as Chairman in 2022. He is also a member of the International Myeloma Working Group (IMWG).
Dr. Stadtmauer is widely published on the subjects of multiple myeloma, acute and chronic leukemia, and bone marrow transplantation and CAR T cell therapy. He has been appointed to the editorial boards of the Leukemia, Journal of Clinical Oncology and Bone Marrow Transplantation. His works have appeared in such premier peer-reviewed journals as the New England Journal of Medicine, Journal of Clinical Oncology, Science, British Journal of Haematology, Blood, Bone Marrow Transplantation, Biology of Blood and Marrow Transplantation, JAMA, Nature Medicine, Lancet Oncology, Science Translational Medicine and Annals of Internal Medicine. He has been a member of the Career Development Award Selection Committee for the Leukemia and Lymphoma Society. His work has ranged from conducting the definitive study of autologous bone marrow transplant for breast cancer to pioneering clinical trials with cellular immunotherapy, CRISPR genetic engineering and vaccination for blood cancers.
Dr. Stadtmauer graduated with an AB degree with distinction in biochemistry from Cornell University and then completed his MD at the University of Pennsylvania School of Medicine. He served his internship and residency in internal medicine at the Albert Einstein College of Medicine in the Bronx, NY. He completed his Fellowship in Hematology/Oncology at the University of Pennsylvania where he founded the Bone Marrow Transplant Program in 1987 and the Myeloma Program in 1999. He has been awarded the DuPont Guerry, IV, MD Award for Outstanding Mentorship, University of Pennsylvania School of Medicine, the Headstrong Achievement Award for advancement and achievements in the fight against cancer, and the Distinguished Partner in Hope Award for dedication to blood cancers’ research and patient care. His name has appeared for decades in the ‘Best Doctors in America’, ‘Best Doctors in America for Cancer’ and as a ‘Top Doc’ in Philadelphia Magazine.
First and Second-Line Treatment Protocols for Multiple Myeloma
Two experts provide a comprehensive overview of the first-line and second-line treatment options for multiple myeloma.